| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-10-22 | Amgen (USA - CA) Roche (Switzerland) | rights to filgrastim and pegfilgrastim in approximately 100 markets | licensing |
Cancer - Oncology | Licensing agreement | |
| 2013-10-22 | Roche (Switzerland) Samsung Biologics (South Korea) | undisclosed Roche\'s commercial biologic medicines | manufacturing |
undisclosed | Production agreement | |
| 2013-10-22 | Beactica (Sweden) Boehringer Ingelheim (Germany) | hits against oncology-relevant kinases of therapeutic interest to Boehringer Ingelheim | R&D |
Cancer - Oncology | R&D agreement | |
| 2013-10-22 | DBV Technologies (France) Inserm (France) Inserm Transfert (France) | epicutaneous delivery of recombinant Factor VIII (FVIII) protein via Viaskin | hemophilia A | R&D |
Genetic diseases - Hematological diseases - Rare diseases | R&D agreement |
| 2013-10-22 | EPIRUS Switzerland (Switzerland - USA) - Orygen Biotecnologia (Brazil) | BOW015 (biosimilar version of Remicade® (infliximab)) | rheumatoid arthritis | development manufacturing production commercialisation | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Production agreement |
| 2013-10-21 | Evotec (Germany) AstraZeneca (UK) | compounds and targets with novel mechanisms that have disease-modifying potential for the treatment of chronic kidney disease | chronic kidney disease | R&D |
Kidney diseases - Renal diseases | R&D agreement |
| 2013-10-21 | Qiagen (The Netherlands) Clovis Oncology (USA) | companion diagnostic targeting drug-resistant EGFR mutations to guide the use of CO-1686 | non-small cell lung cancer (NSCLC) | development |
Cancer - Oncology | Development agreement |
| 2013-10-18 | DBV Technologies (France) Stallergènes (France) | aeroallergens | respiratory allergies | R&D |
Allergic diseases - Immunological diseases | R&D agreement |
| 2013-10-18 | Ablynx (Belgium) Eddingpharm (China) | ALX-0141 | all indications, including osteoporosis and bone metastases | licensing |
Bone diseases - Cancer - Oncology | Licensing agreement |
| 2013-10-17 | AmpliPhi BioSciences (USA - VA) Leicester University (UK) | bacteriophage therapy targeting Clostridium difficile | Clostridium difficile infection | collaboration licensing |
Infectious diseases | Collaboration agreement |
| 2013-10-17 | AstraZeneca (UK) National Research Program for Biopharmaceuticals (NRPB) (Taiwan) | collaboration |
Cardiovascular diseases - Metabolic diseases - Respiratory diseases - Inflammatory diseases - Autoimmune diseases - Cancer - Oncology - Infectious diseases - CNS diseases. | Collaboration agreement | ||
| 2013-10-17 | Biocartis (Belgium) Hospital del Mar (Spain) | EGFR biomarker for colon cancer | colon cancer | development |
Cancer - Oncology | Development agreement |
| 2013-10-16 | Sartorius Stedim Biotech (Germany - France) BD Diagnostics (USA) | ready-to-use, prefilled media products for microbiological applications in pharmaceutical, biotech and research laboratories | development |
Technology - Services | Development agreement | |
| 2013-10-16 | Pieris (Germany) Zydus Cadila (India) | Anticalin®-based protein therapeutics including PRS-110 | development |
Cancer - Oncology | Development agreement | |
| 2013-10-16 | AstraZeneca (UK) Wyss Institute for Biologically Inspired Engineering - Harvard University (USA - MA) | human organs-on-chips, animal organs-on-chips | collaboration |
Technology - Services | Collaboration agreement | |
| 2013-10-16 | Diaxonhit (France) Tosoh (Japan) | immunoassay instruments | commercialisation |
Technology - Services | Commercialisation agreement | |
| 2013-10-15 | Medimmune (USA - global biologics arm of AstraZeneca (UK) ADC Therapeutics (Switzerland) | antibody-drug conjugate (ADC) programmes in preclinical development | collaboration |
Cancer - Oncology | Collaboration agreement | |
| 2013-10-15 | PolyTherics (UK) TUBE Pharma (Austria) | antibody drug conjugates (ADCs) | collaboration |
Cancer - Oncology | Collaboration agreement | |
| 2013-10-15 | Symphogen (Denmark) Open Monoclonal Technology (USA) | OmniRat™ and OmniMouse™ transgenic platforms | collaboration |
Collaboration agreement | ||
| 2013-10-15 | AstraZeneca (UK) TARIS Biomedical (USA) | bladder cancer | R&D |
Cancer - Oncology | R&D agreement |
